Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

University of Saarland chooses Sectra Education Portal to bridge the gap to clinical reality for radiographer students

Linköping, Sweden – February 19, 2024 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) will provide the University of Saarland with its platform for medical education—Sectra Education Portal. The platform provides real-life clinical cases, which will enhance the educational experiences for radiographer students, as well as elevate self-directed learning and remote studies. By adding Sectra’s solution for medical education to their existing Sectra enterprise imaging solution, they are bridging the gap between education and the clinical

Valmet’s share buy-back program for its share-based incentive plans has ended

Valmet’s share buy-back program for its share-based incentive plans has ended Valmet Oyj’s press release on February 19, 2024 at 9:30 a.m. EET   Valmet has now completed the share buy-back program for its share-based incentive plans. The acquisitions of the own shares began on February 12, 2024, and ended on February 16, 2024. During that period, Valmet acquired in aggregate 100,000 of its own shares for an average price per share of EUR 25.58. The total purchase price paid for the shares was EUR 2,557,818. The shares were acquired at market price in public trading on Nasdaq

Wulff Group Plc’s Financial Statements Release January 1 – December 31, 2023

FINANCIAL STATEMENTS RELEASE | FEBRUARY 19, 2024 AT 9.30 A.M. This is a summary of Wulff Group Plc’s Financial Statements Release January 1–December 31, 2023. The complete report is attached to this stock exchange release as a pdf-file. The report is also available at the website www.wulff.fi Positive profitability development in Q4, a proposal for a growing dividend 1.10.-31.12.2023 BRIEFLY · Net sales decreased by 17.1% and totalled EUR 22.9 million (27.7) · EBITDA was EUR 1.6 million (1.8), and comparable EBITDA was EUR 1.6 million (1.8) · Operating profit (EBIT) was

Continued demand for Quartzene[®] in cool roof paint – Svenska Aerogel receives 3 ton order

Svenska Aerogel receives a call-off order for 3 tons of Quartzene[®] from its French distributor Novcoat. The order thus represents a delivery contract between the two companies for 2024 and will be divided into four deliveries during the year. The material will be used by Novcoat’s customer in cool roof paint.When planning its deliveries for 2024, Novcoat’s customer ordered a total of 3 tons of Quartzene®. The value of the order is 96.8 KEUR.   Tor Einar Norbakk, CEO of Svenska Aerogel, comments: ”This order is a very positive sign for us, as it indicates continued strong growth for

BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium. Now, the company has announced the next step for the theranostic approach and its wish to accelerate clinical development of both uTREAT and uTRACE in parallel. Curasight aims at starting a phase I/IIa basket trial in several indications and in order to finance this updated develoment strategy, the company aims at raising DKK 51.2 million in a rights issue. BioStock contacted CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/

Tagrisso plus chemo approved in US for lung cancer

19 February 2024 Tagrisso with the addition of chemotherapy approved in the  US for patients with EGFR-mutated advanced lung cancer Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority

Notice convening YIT Corporation’s Annual General Meeting

YIT Corporation Stock Exchange Release 19 February 2024 at 09:10 a.m.Notice convening YIT Corporation’s Annual General Meeting The shareholders of YIT Corporation are invited to attend the Annual General Meeting to be held on Thursday,14 March 2024, starting at 11:00 a.m. Finnish time (GMT+2) in Messukeskus Siipi, located at the address Rautatieläisenkatu 3, 00520 Helsinki, Finland. Check-in for those who have registered for the meeting, the distribution of voting tickets and coffee service will start at the meeting venue at 10:00 a.m. Finnish time. Shareholders may also exercise

Invitation to Fourth Quarter 2023 Results

Oslo, 19 February 2024: BlueNord ASA ("BlueNord" or the "Company") will publish its financial results for the fourth quarter of 2023 on Tuesday 20 February 2024 at 07:00 (CET). A webcast presentation, followed by a Q&A session, will be hosted at 10:00 (CET). To join webcast: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240220_4 *** Contact: Cathrine Torgersen, Chief Corporate Affairs OfficerEmail: cathrine.torgersen@bluenord.comPhone: +47 915 28 501

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan may bethe first TROP2-directed antibody drug conjugate for patients with lung cancer AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally

Nordic Mining ASA: Key information relating to the reverse split

Date on which the corporate action was made public: 19 February 2024 Reverse split ratio: 20 old shares give 1 new share Last day including right: 12 March 2024 Ex-date: 13 March 2024 Record date: 14 March 2024 Date of approval: 11 March 2024 A new ISIN number will be issued for the new shares: NO0013162693 Other information: The reverse split is subject to approval by the extraordinary general meeting on 11 March 2024. For further information, please contact CFO Jens Gisle Schnelle, telephone +47 476 60 355 Oslo, 19 February 2024Nordic Mining ASA This

Tagrisso improved PFS in Stage III lung cancer

19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting Positive high-level results from the LAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (

Metso to deliver key crushing and grinding technology to the Hemi Gold Project in Australia

Metso Corporation’s press release on February 19, 2024, at 09:00 a.m. EETAustralian mining company De Grey Mining Limited has awarded Metso orders for a Superior™ MKIII 50-65 primary gyratory crusher and two 14MW Premier™ ball mills. The equipment will be installed at De Grey Mining’s Hemi Gold Project located in the Pilbara region of Western Australia. The combined order value of over EUR 20 million is booked in the Minerals segment’s first-quarter 2024 orders received.  “Our aim with the Hemi Gold Project is to deliver a Tier 1 gold project and make a future top 5 Australian Gold Mine

Nitro Games Oyj: Year-end report January – December 2023

REPORTING PERIOD JANUARY – DECEMBER 2023 · Revenues 8,841.6 KEUR (7,247.9 KEUR). · EBITDA: -1,716.6 KEUR (-2,799.8 KEUR). · EBIT: -3,024.8 KEUR (-3,621.3 KEUR). · Net result: -3,283.1 KEUR (-3,707.6 KEUR). · Earnings per share (EPS) -0.19 (-0.29). · Cash and cash equivalents: 3,825.8 KEUR and 1,199.7 KEUR of short-term receivables (31 December 2023). (All figures are presented in accordance with IFRS and, unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year.) OCTOBER – DECEMBER 2023 · Revenues 2,894.

Nordic Mining ASA: Summons to Extraordinary General Meeting - Reverse Split

Shareholders in Nordic Mining ASA are invited to attend the Extraordinary General Meeting held on Monday 11 March 2024 at 10:00 CET. The general meeting will be held as a virtual meeting, where shareholders will be able to participate electronically via PC, phone or tablet. The Board of Directors proposes that the general meeting resolves a reverse share split in the ratio 20:1, so that 20 shares are consolidated into 1. It is proposed that the Board of Directors is authorized to determine the date and the further process for completion of the reverse share split. Expected dates,

Transaction in Own Shares

    19 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |16/02/2024|+----------------------------------------------------------

The Nomination Committee’s proposal to the Annual General Meeting 2024

STOCKHOLM, February 19[th], 2024. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2024.The Nomination CommitteeThe Nomination Committee consists of the Chairman Gillis Cullin representing Östersjöstiftelsen and the members Ida Marie Lindberg, representing Kjelsmark Holding and Kerstin Valinder Strinnholm, Chairman of the Board of Directors in the Company. Chairman of the Annual General MeetingThe Nomination Committee proposes that Kerstin Valinder Strinnholm is elected as

Notice to Extraordinary General Meeting of Kindred Group plc

Kindred Group plc NOTICE IS HEREBY GIVEN that THE EXTRAORDINARY GENERAL MEETING (“EGM”) of Kindred Group plc (C 39017) (the “Company”) convened in terms of article 135 (1)(b) of the Companies Act (Cap. 386 of the Laws of Malta) will be held on Friday 15 March 2024 at 10:00 am CET at Kindred’s office, Regeringsgatan 25, Stockholm, Sweden.Notice to holders of Swedish Depository Receipts (“SDRs”) Holders of SDRs who wish to exercise their voting right at the EGM must: (i) be registered in the register kept by Euroclear Sweden AB by Tuesday 5 March 2024 (the “Record Date”); and (ii)

PanGenomic Health Announces Withdrawal from AQSE

PanGenomic Health Announces Withdrawal from AQSE   Vancouver, British Columbia, Canada, 19 February 2024 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA) announces its intention to withdraw the Company's Class A Common Shares ("Shares") from the Aquis Stock Exchange Growth Market ("AQSE").   Pursuant to the AQSE Access Rulebook, the Company is required to give 20 business days' notice of its intention to withdraw from trading on AQSE. Therefore, trading in the Shares will cease at 4:30 pm, UK time, on 15 March 2024.   The Shares will

Africa Oil Announces Results of Share Buyback Program

VANCOUVER, BC, Feb. 19, 2024 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased to announce that the Company repurchased a total of 326,250 Africa Oil common shares during the period of February 12, 2024 to February 16, 2024 under the previously announced share buyback program. The launch of Africa Oil’s normal course issuer bid (share buyback) program, announced by the Company on December 4, 2023, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/

Gjensidige Forsikring ASA: Contemplating Subordinated Tier 2 bond issue

Gjensidige Forsikring ASA (“Gjensidige” or “the Company”, OSE:GJF, LEI 5967007LIEEXZX6FAO47), rated A by S&P (stable), has mandated DNB Markets and Nordea Bank Abp as Joint Lead Managers to arrange a digital fixed income investor meeting on Monday 19 February 2024. The company contemplates to issue a new Tier 2 bond issue in NOK with floating interest rate. The issuance may be split in one or more tranches, and each tranche will have a minimum 30-year tenor, and the issuer will have a first call option after minimum 5 years. Expected issue size is up to NOK 800 million, subject to market

Veidekke: Shares purchased by employees in 2024 and Exercise of employee share options by Key employees

2 260 Veidekke employees purchased a total of 1 337 650 shares in the company’s annual employee share scheme. Approximately 12 percent of the shares in the company are currently owned by Veidekke employees. “Employees’ co-ownership is a long-standing tradition in Veidekke. The annual offer to buy shares at a discount provides all Veidekke employees with an opportunity to take part in the group's value creation in the form of dividends and increased share value. Veidekke believes that employees’ share ownership creates added value, by fostering commercial awareness and helping to bring

YIT’s Annual Review for 2023 published

YIT Corporation Stock Exchange Release 19 February 2024 at 09:00 a.m.YIT’s Annual Review for 2023 published YIT’s Annual Review for 2023 has been published today on the company’s website at www.yitgroup.com/annualreports  and as attachments to this stock exchange release. The Annual Review consists of the report of the Board of Directors, consolidated financial statements, parent company’s financial statements and Auditor’s Report. The report of the Board of Directors contains YIT’s statement of non-financial information.

There are no items matching the current filter
There are no more items matching the current filter
Back to top